Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study ‘PolAZA’

Mądry, Krzysztof; Lis, Karol; Tukiendorf, Andrzej; Szwedyk, Paweł; Kapelko-Słowik, Katarzyna; Subocz, Edyta; Gołoś, Aleksandra; W, Makowska; Masternak, Anna; Kopińska, Anna; Czemerska, Magdalena; Zawadzka-Leska, Sara; Rusicka, Patrycja; Drozd‐Sokołowska, Joanna; Wiater, Elżbieta; Hołojda, Jadwiga; Pogłódek, Bartłomiej; Centkowski, Piotr; Waszczuk‐Gajda, Anna; Machowicz, Rafał; Hałka, Janusz; Czerw, Tomasz; Basak, Grzegorz W.; Dwilewicz‐Trojaczek, Jadwiga

doi:10.1080/16078454.2021.1956182

Cited by 5 publications

(2 citation statements)

References 35 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum ALB maintains the normal nutritional state of the human body and colloidal osmotic pressure, such as plasma. Furthermore, it is an indicator of chronic inflammation [6,7,[18][19][20]. Low serum albumin levels resulting from inflammation-induced capillary leakage or disease related anorexia during acute illness are associated with poor outcomes [11,21].…”

Section: Discussionmentioning

confidence: 99%

Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study

Xiao

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is the main type of adult leukemia, and 60-day mortality is a vital clinical problem that doctors have to face at the begin with treatment. Studies on the association between serum albumin and 60-day mortality from AML (non-APL) are limited. Methods In this retrospective cohort study, ALB was measured after admission in all patients diagnosed with primary AML from Affiliated Ganzhou Hospital of Nanchang University between January 2013 and May 2021. The outcome was all-cause, 60-day mortality. Multivariable Cox regression analyses were performed to calculate the adjusted hazard ratio (HR) and its corresponding 95% confidence interval (CI). Results This study included 394 primary AML patients. The overall 60-day mortality was 28.9% (114/394); it was 43.1% (56/130), 27.5% (36/131), and 16.5% (22/133) for ALB quantile1 (Q, < 34.5 g/L), quantile 2 (Q2, 34.5–38.5 g/L), and quantile 3 (Q3, ≥ 38.6 g/L), respectively (P = 0.001). After adjusting for potential confounders, we found an association between a 6% decrease in 60-day mortality rate and a 1 g/L increase in ALB level (HR = 0.94, 95% CI: 0.89–0.99, P = 0.015), which was associated with 38 and 70% decreases in 60-day mortality rates in Q2 (HR = 0.50, 95% CI: 0.30–0.86, P = 0.012) and Q3 (HR = 0.47, 95% CI: 0.2 5–0.90, P = 0.022), respectively, compared with that in Q1. Similar results were obtained after subgrouping based on an ALB level of 35 g/L (HR = 0.55, 95% CI: 0.34–0.88, P = 0.013). Conclusions Serum albumin was significantly associated with 60-day mortality of primary AML, which has important clinical significance. Further investigation is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study

Xiao

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Although the toxic effect of AZA manifests as myelosuppression, the addition of eltrombopag, lenalidomide or vorinostat to AZA therapy can worsen the effect and aggravate the toxicity [2]. To prevent progression, it is suggested to check serum albumin level, because its low level can increase the risk of infections and can be used as a prognostic factor in AZA therapy [32].…”

Section: Hypomethylating Drugsmentioning

confidence: 99%

Therapeutic options in high-risk myelodysplastic syndrome

Maksymowicz

Moqbil

Machowiec

et al. 2023

Hematology in Clinical Practice

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) constitute a heterogeneous group of diseases characterised by ineffective haematopoiesis, dysplasia and cytopenias. The treatment for high-risk MDS (HR-MDS) depends on individual factors such as the stage of the disease, age, comorbidities, and infections.Allogeneic haematopoietic stem cell transplantation (allo-HSCT) with reduced intensity conditioning has allowed more HR-MDS patients to be transplant-eligible, regardless of age. Hypomethylating agents, including azacitidine and decitabine, remain the standard of care for HR-MDS patients who are not qualified for curative allo-HSCT. Combination therapy of azacitidine with some new drugs resulted in higher response rates than azacitidine in monotherapy. Other targeted therapies are under investigation. They include HMA with different antibodies targeting immune checkpoints -programmed cell death (ligand) 1, cytotoxic T lymphocyte antigen 4, T-cell immunoglobulin mucin-3 or cluster of differentiation 47. Larger studies are necessary to confirm their efficacy in the treatment of HR-MDS.

show abstract

Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system

et al. 2023

View full text Add to dashboard Cite

Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study ‘PolAZA’

Abstract: Dwilewicz-Trojaczek (2021) Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients -results of the PALG study '

Cited by 5 publications

References 35 publications

Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study

Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study

Therapeutic options in high-risk myelodysplastic syndrome

Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system

Contact Info

Product

Resources

About